Virulence mechanisms are essential for host infection and persistence, and therefore selectively targeting these bacterial traits has emerged as an attractive strategy in drug design.13 In this regard, ‘anti-virulence’ agents or ‘pathoblockers’ may directly interfere with the biosynthesis, secretion, or function of specific virulence factors or disturb/disrupt higher regulatory systems which control the production of virulence arsenals.34